HOOKIPA Pharma Inc
HOOK0.899USD
+0.014+1.52%
Market hours （ET）Quotes delayed by 15 min
10.85MMarket Cap
LossP/E TTM
More Details of HOOKIPA Pharma Inc Company
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Company Info
Ticker SymbolHOOK
Company nameHOOKIPA Pharma Inc
IPO dateApr 18, 2019
CEODr. Malte Peters, M.D.
Number of employees82
Security typeOrdinary Share
Fiscal year-endApr 18
Address350 Fifth Avenue, 72Nd Floor, Suite 7240
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10118
Phone114318906360
Websitehttps://www.hookipapharma.com/
Ticker SymbolHOOK
IPO dateApr 18, 2019
CEODr. Malte Peters, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
496.00
-0.20%
Mr. Sean A. Cassidy
Mr. Sean A. Cassidy
Independent Director
Independent Director
--
--
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Dr. David R. Kaufman, M.D., Ph.D.
Dr. David R. Kaufman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Terry Coelho
Ms. Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Chief Financial Officer, Executive Vice President, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
496.00
-0.20%
Mr. Sean A. Cassidy
Mr. Sean A. Cassidy
Independent Director
Independent Director
--
--
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Dr. David R. Kaufman, M.D., Ph.D.
Dr. David R. Kaufman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Terry Coelho
Ms. Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Chief Financial Officer, Executive Vice President, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jun 15
Updated: Sun, Jun 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
19.14%
Baker Bros. Advisors LP
8.29%
Invus Public Equities Advisors, LLC
5.78%
Knoll Capital Management, LLC
5.09%
Fidelity Management & Research Company LLC
3.43%
Other
58.26%
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
19.14%
Baker Bros. Advisors LP
8.29%
Invus Public Equities Advisors, LLC
5.78%
Knoll Capital Management, LLC
5.09%
Fidelity Management & Research Company LLC
3.43%
Other
58.26%
Shareholder Types
Shareholders
Proportion
Corporation
19.16%
Hedge Fund
14.51%
Investment Advisor
13.49%
Venture Capital
3.38%
Investment Advisor/Hedge Fund
2.53%
Research Firm
0.25%
Individual Investor
0.13%
Other
46.54%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
100
5.23M
53.40%
-1.44M
2025Q1
107
5.24M
53.53%
-1.53M
2024Q4
113
5.54M
57.39%
-1.29M
2024Q3
117
5.65M
62.13%
+370.86K
2024Q2
126
5.73M
65.67%
+16.62K
2024Q1
159
5.79M
66.36%
+211.50K
2023Q4
171
5.72M
72.26%
+846.00
2023Q3
186
4.97M
68.46%
-1.10M
2023Q2
191
5.35M
75.93%
+1.70M
2023Q1
193
3.07M
61.74%
-790.10K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences Inc
1.88M
19.16%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
812.81K
8.3%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
566.64K
5.79%
--
--
Mar 31, 2025
Knoll Capital Management, LLC
498.63K
5.09%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
336.46K
3.44%
-3.66K
-1.08%
Mar 31, 2025
Sofinnova Partners
314.26K
3.21%
+314.26K
--
Feb 14, 2025
The Vanguard Group, Inc.
300.82K
3.07%
+87.60K
+41.08%
Mar 31, 2025
Geode Capital Management, L.L.C.
73.43K
0.75%
+835.00
+1.15%
Mar 31, 2025
Acadian Asset Management LLC
55.73K
0.57%
-4.92K
-8.12%
Mar 31, 2025
Ikarian Capital LLC
53.00K
0.54%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
Date
Type
Ratio
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
